|
Statement
| 1.Date of amendment to the contract or commitment:2022/08/09
2.Counterparty of the contract or commitment:Skyline Vet Pharma, Inc.
3.Relationship with the Company:not applicable
4.Reason for amendment:Revision of the licensing terms for the veterinary
analgesic.
5.Content amended:
(1) The Exclusive Licensing Agreement for the long-acting analgesic
injection for animals made with Skyline Vet Pharma (SVP) was amended and
was originally approved by Lumosa Board on May 31st, 2022. The changes
were made to reflect the adjustment of upfront fee and milestone payments
to USD900,000, and the revision of the percentage of the sub-license fee
and royalty payments from the sales.
(2) After the revision, the upfront fee and milestone payments are reduced
from USD900,000 to USD300,000, however, the percentage of sub-licensing
revenue and royalty payments are increased.
6.Effect on the Company's finances or business:
This matter has positive long-term and short-term effect on
the company's operations.
7.Any other matters that need to be specified:
(1) SVP is a US veterinary pharmaceutical development company engaged in
the research, development, and marketing of veterinary pharmaceutical
products.
(2) The specific information regarding the milestones, sharing ratio from
SVP's sub-licensing fees, and royalty payments are regarded as
confidential according to the non-disclosure agreement between both
parties. The revenue contributed by this agreement in the future will be
disclosed monthly on the Public Information Observatory website or be
released in the audited or reviewed financial reports.
(3) Taiwan Ministry of Science and Technology and National Defense Medical
Center licensed the exclusive development and commercialization rights
and relevant technologies of LT1001 to Lumosa. In turn, Lumosa shall pay
20% of considerations from the sub-license fee to the licensor, as well
as 1.875%~3.75% royalty from the sales of LT1001 long-acting analgesic
injection.
(4) New drug development requires a long process, vast investments, and no
guarantee of success which may pose investment risks.
Investors are advised to exercise caution and conduct a thorough
evaluation.
|
